中国批准首种本国生产的九价HPV疫苗Cecolin 9,旨在降低子宫颈癌风险。 China approves its first homegrown 9-valent HPV vaccine, Cecolin 9, aiming to reduce cervical cancer risks.

中国已批准其第一种国内研发的九价HPV疫苗,称为Cecolin 9疫苗,结束了外国在市场上的支配地位。 China has approved its first domestically developed 9-valent HPV vaccine, called Cecolin 9, ending foreign dominance in the market. 疫苗由Xiamen大学和生物技术公司开发,目标是九种HPV菌株,以减少宫颈癌和其他HPV相关疾病的风险。 Developed by Xiamen University and biotech firms, the vaccine targets nine HPV strains, reducing risks for cervical cancer and other HPV-related diseases. 这使中国成为第二个生产这种疫苗的国家,仅次于美国,提高了疫苗的可获得性,并有可能降低成本。 This makes China the second country, after the US, to produce such a vaccine, enhancing vaccine accessibility and potentially lowering costs.